Elicera Therapeutics: Receives orphan drug designation in the US for ELC-100 in pancreatic neuroendocrine tumors - Redeye

Redeye endorses today’s news that Elicera has received an orphan drug designation in the US for ELC-100 in pancreatic neuroendocrine tumors, which we had expected the drug candidate to receive eventually. The ODD adds additional protection, including up to seven years of market exclusivity in the US. In the press release, Elicera states that it expects “ to report the final data from the first part of the study around mid-2025”. We also note that the share price has rallied significantly lately, which bodes well for the company’s warrant program if continued, which would increase the financial flexibility and likely lead us to reduce our assumption of further capital need.

Länk till analysen i sin helhet: https://www.redeye.se/research/1067602/elicera-therapeutics-receives-orphan-drug-designation-in-the-us-for-elc-100-in-pancreatic-neuroendocrine-tumors?utm_source=finwire&utm_medium=RSS